GNI’s China-based affiliate, Shanghai Genomics, is in the process of preparing its Phase I trial for the drug, F351.
Jun Wu‚ chief scientific officer of GNI, and Shanghai Genomics, said: “We have shown that F351 specifically inhibits over-production of collagen by liver fibroblasts following inflammatory insults. The possibility to intervene in such inflammatory process has enormous relevance to the treatment of fibrotic diseases in humans.”